In a recently published paper, Melhim et al. showed that CMP-001 alone or in combination with pembrolizumab (PD-1 inhibitor) in patients with advanced melanoma is tolerable and capable of reversing anti-PD1 resistance therapy with durable and strong clinical responses [139]. Here, SNCA is linked to melanoma.